ID: MRFR/Pharma/2180-HCR | February 2021 | Region: Global | 60 pages
Diabetes is a chronic metabolic disease that cause high blood sugar due to which body becomes incapable of producing insulin. According to World Health Organization (WHO), India had 69.2 million people living with diabetes (8.7%) in 2015. About 90% of the patients are suffering from Type 2 diabetes. Increasing awareness, increasing number of patients, untouched rural market, increasing urbanization, developing healthcare infrastructure and increasing spending on healthcare are driving the market for diabetes in India. India Diabetes Market size is expected to grow at an average CAGR of 6.5% during 2016-2023. The Market is growing rapidly. India Diabetes Market is expected to grow US$ 7441.6 million by 2023 from US$ 4778.7 million in 2016.
Study objectives of India Diabetes Market:
India Diabetes Market Share by Devices, 2016 (%):
India Diabetes Market has been segmented on the basis of type which comprise Type 1, Type 2, and Gestational diabetes. On the basis of test market is segmented into Random blood sugar test, Fasting blood sugar test, Oral glucose tolerance test, Initial glucose challenge test and others. On the basis of devices, it is segmented into Blood glucose monitoring devices, Diabetes management devices, and others. On the basis of treatment, the market is segmented into Medications, Insulin therapy, Transplantation, Bariatric surgery and others.
Considering the scenario of the Indian diabetes market, western region is believed to be the largest market for diabetes. Moreover the Eastern and Northern regions are also growing and second-largest market for India Diabetes. On the other hand, Southern Indian market is expected to grow at a significant rate in India diabetes during the forecasted period. Central region is likely to have a limited but moderate growth in the market.
|Market Size||USD 7441.6 Million|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Type, Test, Devices, Treatment|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||Novo Nordisk A/S (Denmark), USV Private Limited (India), sanofi-aventis U.S. LLC (US), Novartis AG (Switzerland), Merck & Co., Inc. (US), Becton Dickinson and Company (US), Roche Diabetes Care, Inc.(US),Johnson & Johnson Services, Inc.(us), Bayer AG (Germany), Ypsomed (Switzerland)|
|Key Market Opportunities||Research and developments|
|Key Market Drivers||